📣 VC round data is live. Check it out!

Masimo Valuation Multiples

Discover Masimo's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Baxter International, Insulet, Bruker, Demant and more.

Masimo Overview

About Masimo

Masimo Corp is a technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.


Founded

1989

HQ

United States

Employees

9.2K

Website

masimo.com

Financials (LTM)

Revenue: $2B
EBITDA: $475M

EV

$10B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Masimo Financials

Masimo reported last 12-month revenue of $2B and EBITDA of $475M.

In the same LTM period, Masimo generated $475M in EBITDA and $17M in net income.

Revenue (LTM)


Masimo P&L

In the most recent fiscal year, Masimo reported revenue of $2B and EBITDA of $495M.

Masimo is profitable as of last fiscal year, with gross margin of 58%, EBITDA margin of 30%, and net margin of 15%.

See analyst estimates for Masimo
LTMLast FY202320242025202620272028
Revenue$2B$2B$2B$2B$2B
Gross Profit-$945M$1B$1B-
Gross Margin-58%49%48%-
EBITDA$475M$495M$237M($159M)$461M
EBITDA Margin30%30%12%(8%)30%
EBIT Margin24%28%8%2%20%
Net Profit$17M$248M$82M($305M)($152M)
Net Margin1%15%4%(15%)(10%)
Net Debt-$372M---

Financial data powered by Morningstar, Inc.

Masimo Stock Performance

Masimo has current market cap of $9B, and enterprise value of $10B.

Market Cap Evolution


Masimo's stock price is $178.71.

Masimo share price increased by 0.1% in the last 30 days, and by 6.2% in the last year.

Masimo has an EPS (earnings per share) of $4.74.

See more trading valuation data for Masimo
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$10B$9B0.1%0.1%0.5%6.2%$4.74

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Masimo Valuation Multiples

Masimo trades at 6.2x EV/Revenue multiple, and 20.4x EV/EBITDA.

See NTM and 2027E valuation multiples for Masimo

EV / Revenue (LTM)


Masimo Financial Valuation Multiples

As of June 3, 2026, Masimo has market cap of $9B and EV of $10B.

Masimo has a P/E ratio of 548.7x.

LTMLast FY202320242025202620272028
EV/Revenue6.2x6.0x4.7x4.6x6.4x
EV/EBITDA20.4x19.7x41.1x(61.2x)21.1x
EV/EBIT26.3x21.5x59.2xn/m31.4x
EV/Gross Profit-10.3x9.7x9.7x-
P/En/m37.7x114.8x(30.7x)(61.8x)
EV/FCF49.6x45.2xn/m66.9x53.4x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Masimo Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Masimo Margins & Growth Rates

Masimo grew revenue by 8% and EBITDA by 12% in the last fiscal year.

In the most recent fiscal year, Masimo reported gross margin of 58%, EBITDA margin of 30%, and net margin of 15%.

See estimated margins and future growth rates for Masimo

Masimo Margins

Last FY202420252026202720282029
Gross Margin58%48%-62%
EBITDA Margin30%(8%)30%23%
EBIT Margin28%2%20%20%
Net Margin15%(15%)(10%)(10%)
FCF Margin13%7%12%13%

Masimo Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth8%2%(27%)0%
Gross Profit Growth-0%--
EBITDA Growth12%(167%)(391%)(25%)
EBIT Growth11%(77%)720%1%
Net Profit Growth16%(474%)(50%)0%
FCF Growth-2170%25%6%

Data powered by FactSet, Inc. and Morningstar, Inc.

Masimo Operational KPIs

Masimo's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Masimo's Rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Masimo's Rule of X is 23% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Masimo
LTMLast FY20232024202620272028
Rule of 4037%23%--
Bessemer Rule of X48%23%--
Revenue per Employee-$0.2M--
Opex per Employee-$0.1M--
R&D Expenses to Revenue-8%9%11%
Opex to Revenue-39%41%46%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Masimo Competitors

Masimo competitors include Baxter International, Insulet, Bruker, Demant, Bio-Rad Laboratories, Globus Medical, Zydus Lifesciences, Fresenius Medical Care, Cooper Companies and Shimadzu.

Most Masimo public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Baxter International1.5x1.5x7.6x7.8x
Insulet3.8x3.5x16.1x14.5x
Bruker3.0x2.9x19.2x17.6x
Demant3.1x3.0x13.1x12.6x
Bio-Rad Laboratories3.1x3.1x6.6x18.1x
Globus Medical3.4x3.3x11.0x10.3x
Zydus Lifesciences4.2x4.1x13.4x15.8x
Fresenius Medical Care1.0x1.0x5.2x5.3x

This data is available for Pro users. Sign up to see all Masimo competitors and their valuation data.

Start Free Trial

Acquisitions by Masimo

Masimo has acquired 4 companies to date.

Last acquisition by Masimo was on April 20th 2023. Masimo acquired nura for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by Masimo

nura
Sound United
Lidco
TNI medical
Description
nura is an Australian audio company known for the Nuraphone headphones, which feature biometric sensors to measure hearing profiles from outer ear to brain and customize sound output. Founded in 2014 in Melbourne, the technology adapts EQ settings automatically upon wear detection. The Nuraphone supports wireless Bluetooth connectivity and immersive 360-degree audio. nura has expanded to true wireless earbuds and sells through retailers in Europe, Asia, and North America, with patents on its sensory technology.
Sound United is a consumer audio company owning brands Polk Audio, Definitive Technology, and Denon home theater systems. Montebello, California-headquartered after a 2017 merger with D+M Holdings, it manufactures wireless speakers, soundbars, and AV receivers distributed globally via Best Buy and Amazon. The portfolio includes Marantz hi-fi amplifiers and HEOS multi-room streaming compatible with AirPlay 2.
LiDCO is a Cambridge-headquartered medical device company manufacturing non-invasive and minimally invasive hemodynamic monitoring systems. Its LiDCOplus and LiDCOrapid monitors measure pulse contour analysis for cardiac output, oxygen delivery, and fluid responsiveness in ICU and surgical settings. Deployed in over 2,000 hospitals globally, the technology supports goal-directed therapy reducing complications in high-risk patients. Since introducing its first product in 1999, LiDCO integrates with existing clinical monitors for real-time hemodynamic optimization.
TNI medical is a medical device company headquartered in Freiburg, Germany, specializing in non-invasive respiratory therapy equipment. The firm develops the SoftFlow system, a high-flow nasal cannula device that delivers heated, humidified oxygen to improve patient comfort during ventilation. Production facilities operate in Würzburg and Dessau in Germany, alongside a U.S. site in Baltimore, Maryland. Founded in 2007, TNI medical distributes its products to hospitals and clinics worldwide, emphasizing therapy for chronic obstructive pulmonary disease and acute respiratory distress.
HQ CountryAustraliaUnited StatesUnited KingdomGermany
HQ City
Melbourne
San Diego, CA
London
Freiburg
Deal Date20 Apr 202315 Feb 20222 Nov 202020 Mar 2020
Valuationundisclosed$1B$40M$33M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Masimo acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Masimo

Masimo has invested in 1 company to date.

Latest investment by Masimo was on January 3rd 2018. Masimo invested in StartUp Health in their $19M Undisclosed stage round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Masimo

StartUp Health
Description
StartUp Health is a New York-headquartered venture platform founded in 2011 that invests in over 400 health technology companies spanning six continents and 26 countries. Its portfolio targets moonshots in access to care, disease cures, women's health, mental health, longevity, and pandemic response, with companies collectively raising more than $2 billion. Backed by investors such as Kaiser Permanente, Novartis, Steve Case, and Mark Cuban, the platform delivers decade-long support including capital, expert networks, and strategic collaborations.
HQ CountryUnited States
HQ City
New York City, NY
Deal Date3 Jan 2018
RoundUndisclosed stage
Raised$19M
InvestorsGuideWell; Masimo; Ping An
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Masimo investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Masimo

When was Masimo founded?Masimo was founded in 1989.
Where is Masimo headquartered?Masimo is headquartered in United States.
How many employees does Masimo have?As of today, Masimo has over 9K employees.
Who is the CEO of Masimo?Masimo's CEO is Catherine M. Szyman.
Is Masimo publicly listed?Yes, Masimo is a public company listed on Nasdaq.
What is the stock symbol of Masimo?Masimo trades under MASI ticker.
When did Masimo go public?Masimo went public in 2007.
Who are competitors of Masimo?Masimo main competitors include Baxter International, Insulet, Bruker, Demant, Bio-Rad Laboratories, Globus Medical, Zydus Lifesciences, Fresenius Medical Care, Cooper Companies, Shimadzu.
What is the current market cap of Masimo?Masimo's current market cap is $9B.
What is the current revenue of Masimo?Masimo's last 12 months revenue is $2B.
What is the current revenue growth of Masimo?Masimo revenue growth (NTM/LTM) is 7%.
What is the current EV/Revenue multiple of Masimo?Current revenue multiple of Masimo is 6.2x.
What is the current EBITDA of Masimo?Masimo's last 12 months EBITDA is $475M.
What is Masimo's EBITDA margin?Masimo's last 12 months EBITDA margin is 30%.
What is the current EV/EBITDA multiple of Masimo?Current EBITDA multiple of Masimo is 20.4x.
What is the current FCF of Masimo?Masimo's last 12 months FCF is $196M.
What is Masimo's FCF margin?Masimo's last 12 months FCF margin is 12%.
What is the current EV/FCF multiple of Masimo?Current FCF multiple of Masimo is 49.6x.
How many companies Masimo has acquired to date?As of June 2026, Masimo has acquired 4 companies.
What was the largest acquisition by Masimo?$1B acquisition of Sound United on 15th February 2022 was the largest M&A Masimo has done to date.
What companies Masimo acquired?Masimo acquired Sound United, Lidco, TNI medical, and nura.
In how many companies Masimo has invested to date?As of June 2026, Masimo has invested in 1 company.
What was the last Masimo investment?On 3rd January 2018 Masimo invested in StartUp Health, participating in a $19M Undisclosed stage round, alongside GuideWell and Ping An.
In what companies Masimo invested in?Masimo invested in StartUp Health.

See public comps similar to Masimo

Lists including Masimo

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial